GENova Biotherapeutics, Inc. (GVBP.OB) to Acquire Drug Patents Worth Over $1 Billion in Royalties
With great excitement, GENova Biotherapeutics, Inc., a biotechnology company that develops proteins to disrupt the advance of life-threatening diseases, recently announced that it is in the process of acquiring three promising new drug target patents that could generate over a billion dollar in royalty fees in the mid to long term. Aaron Whiteman, CEO for GENova commented, "Following a rigorous evaluation phase, we have selected three potential blockbuster drug target patents for acquisition, and we look forward to integrating them into our IP portfolio." GENova will announce details of these new biological products in the coming weeks. The three new…